FDA expands use of Vibativ (Theravance) to treat Gospital Acquired Pneumonia
The FDA on 21 June 2013 expanded the approved use of the antibiotic Vibativ (telavancin) from Theravance, to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Vibativ should be used for the treatment of HABP/VABP only when alternative treatments are not suitable.
Vibativ is approved only to treat S. aureus, not other bacteria that cause pneumonia. HABP/VABP, also known as nosocomial pneumonia, is a particularly serious lung infection because patients in the hospital and especially those on ventilators are often already very sick and usually cannot fight the infection.
Vibativ was EU approved to treat Nosocomial Pneumonis caused by MRSA in September 2011.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins